Objective: To describe the safety, tolerability, and pharmacodynamics (PD) of emraclidine 30 mg once daily (QD) and emraclidine 20 mg twice daily (BID) in patients with acute schizophrenia.
Objective: To describe the safety, tolerability, and pharmacodynamics (PD) of emraclidine 30 mg once daily (QD) and emraclidine 20 mg twice daily (BID) in patients with acute schizophrenia.
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.